Autopsy report · NCT00478972

Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients on Diet and Exercise

“Company decision taken in light of demands by certain national health authorities”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month after it had already started.
• Ran for about 1 year 9 months before it stopped.
• 321 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Sanofi

Sponsor type

Industry

Conditions

Obesity; Diabetes Mellitus Type 2

Interventions

Rimonabant; placebo (for Rimonabant); Diet and exercise

Participants

321

Sites

1

Countries

Japan

Trials that died the same way

• 3D011-08 Monotherapy in Subjects With Advanced Solid Tumors
  “Company's decision” (65% match in meaning)
• Trial Investigating the Safety and Efficacy of BRC-003 in Refractory Post-Traumatic Epilepsy
  “Company decision” (65% match in meaning)
• V-Chordal Adjustable System for Chordal Replacement in Mitral Valve Insufficiency Due to Leaflet Prolapse
  “Company business decision” (62% match in meaning)
• Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders
  “Company decision (not a safety issue)” (61% match in meaning)
• A Study of TAK-102 in Adult With Previously-Treated Solid Tumors
  “Business decision unrelated to patient safety” (61% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.